⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909574 | 0.90 | — | — | |
| SCHEMBL10473433 | 0.80 | TSHR (0.36) | — | |
| SCHEMBL29324533 | 0.78 | — | — | |
| SCHEMBL42315 | 0.77 | — | — | |
| SCHEMBL28006277 | 0.74 | — | — | |
| SCHEMBL28508223 | 0.73 | — | — | |
| SCHEMBL487300 | 0.73 | — | — | |
| SCHEMBL20495555 | 0.72 | — | — | |
| SCHEMBL487371 | 0.71 | USP2 (0.31) | — | |
| SCHEMBL202959 | 0.71 | USP2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | claimed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | claimed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | claimed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | claimed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | claimed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | claimed |
| EP-3154956-A1 | GLUCAGON ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| EP-3153501-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2017-04-12 | — | — | EP | claimed |
| WO-2015191900-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| CN-104803891-A | Glucagon antagonists | METABASIS THERAPEUTICS INC | 2015-07-29 | — | — | CN | claimed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | claimed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | claimed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | claimed |
| JP-2012500212-A | — | — | 2012-01-05 | — | — | JP | claimed |
| CN-102292316-A | Glucagon antagonists | — | 2011-12-21 | — | — | CN | claimed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | claimed |